Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trials.
about
Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trials.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Development of draft validatio ...... dyloarthritis clinical trials.
@en
type
label
Development of draft validatio ...... dyloarthritis clinical trials.
@en
prefLabel
Development of draft validatio ...... dyloarthritis clinical trials.
@en
P2093
P50
P1476
Development of draft validatio ...... dyloarthritis clinical trials.
@en
P2093
Dick Heinegard
Hani El-Gabalawy
John Matyas
Maarten Boers
Patrick Garnero
Piet Geusens
Stefan Lohmander
Tore Saxne
Virginia B Kraus
P304
P407
P577
2007-03-01T00:00:00Z